Skip to content
StockMarketAgent
Direct answer
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities. Fair value range: low $654, high $2709, with mid-point at $1486.
Stock analysis

ARGX fair value $654–$2,709

By StockMarketAgent.AI team· supervised by
تم التحليل: 2026-05-20التحديث التالي: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Hyper-growth
View archive
السعر
$797.77
▲ +688.71 (+86.33%)
القيمة العادلة
$1486
$654–$2709
التصنيف
شراء قوي
confidence 82/100
إمكانية الصعود
+86.3%
upside to fair value
هامش الأمان
$1263.51
MoS level · 15%
القيمة السوقية
$49.9B
P/E fwd 21.8
المصدر الإنجليزيAR
يتم عرض المصدر الإنجليزي أثناء الترجمة
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.

§1 الملخص التنفيذي

  • Commercial-stage status with visible traction in gMG/CIDP provides a reliable valuation floor.
  • Robust pipeline diversity reduces binary outcome risk compared to single-asset biotechs.
  • Forward earnings captures the massive earnings reset expected as assets reach peak penetration.
Fair value
$1,486
Margin of safety
+46.3%
Confidence
82/100
Moat
6.5/10

Educational analysis only — not financial advice. Always do your own due diligence.

$797.77Price
Low $654.18
Mid $1,486.48
High $2,709.48

argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.

  • IP-protected antibody platform
    IP-protected antibody platform
  • Pipeline-in-a-product strategy
    Pipeline-in-a-product strategy
  • Cycle upside
    High demand for specialized autoimmune therapeutic platforms.

§2 السيناريو الهبوطي

In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.

كيف يمكن أن تفشل هذه الأطروحة

FcRn Class Competition

· Medium

Next-generation competitors outcompete on pricing or efficacy, eroding market share.

FV impact
Severe

Secondary Indication Failures

· Low

Regulatory delays or clinical failures across 3+ secondary indications cap revenue.

FV impact
Moderate

Margin Compression

· Medium

Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.

FV impact
Moderate
إشارات الإنذار المبكر للمراقبة
المقياسالحاليحد التشغيل
Operating margins failing to cross 15% by FY2027.MonitorDeterioration versus the report thesis
Regulatory rejection in secondary indications.MonitorDeterioration versus the report thesis
Clinical failure across more than 3 secondary indications.MonitorDeterioration versus the report thesis
Loss of market share in gMG to competitors.MonitorDeterioration versus the report thesis
Sustained increase in SG&A without revenue growth.MonitorDeterioration versus the report thesis

§3 التاريخ المالي

بيان الدخل — آخر ستة فترات
البندT−0T−1T−2T−3معدل النمو السنوي المركب
الفترة2022-12-312023-12-312024-12-312025-12-31Trend
الإيرادات$410.7M$1.23B$2.19B$4.15B+116.2%
إجمالي الربح$381.3M$1.11B$1.96B$3.70B+113.3%
الدخل التشغيلي$-723.9M$-420.6M$-17.8M$1.05B—
صافي الدخل$-709.6M$-295.1M$833.0M$1.29B—
EPS (مخفف)$-13.05$-5.16$12.78$19.57—
EBITDA$-622.8M$-192.3M$105.2M$1.31B—
البحث والتطوير$663.4M$859.5M$983.4M$1.36B+27.2%
المصاريف الإدارية والبيعية$469.9M$709.5M$1.05B$1.36B+42.5%

درجات الجودة

OCF / صافي الدخل
0.53×
>1 يشير إلى جودة عالية للأرباح
حد جودة المحاسبة
Fail
حد معدل حسب القطاع
ROIC
13.8%
العائد على رأس المال المستثمر
القسم 3

Numbers analysis

التدفق النقدي

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

تخصيص رأس المال

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

المشتركون الأفراد — من §4 فصاعداً11 قسماً إضافياً

اقرأ التحليل الكامل — 11 قسماً إضافياً.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

تقرير كامل لكل سهم مغطى
أرشيف تصنيفات 24 شهراً
إيجازات قائمة المراقبة + تنبيهات تغيير التصنيف
تصدير PDF + DOCX بأي لغة
ابدأ تجربة مجانية
إلغاء في أي وقت.
FAQ

ARGX — frequently asked questions

  1. Based on our latest analysis, ARGX looks meaningfully undervalued. The current price is $798 versus a composite fair-value midpoint of $1486 (range $654–$2709), which implies roughly 86.3% upside to the midpoint.

Related coverage

Names readers of ARGX also follow

Same archetype: hyper-growth